Rapport Therapeutics Inc., a clinical-stage biotechnology company, will host its inaugural Investor and Analyst Day on June 2, 2025, in New York City. The event will focus on the company's clinical programs, highlighting the RAP-219 Phase 2a trial in refractory focal epilepsy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455353-en) on May 21, 2025, and is solely responsible for the information contained therein.